7LK Pomegranate Cloud Medical received a listing filing notice for U.S. stock market, may become the first Chinese chronic disease medical service stock in U.S. market.
On January 17, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice (Guohe Han [2025] No. 115) regarding the overseas issuance and listing of Guangzhou 7LK Digital Health Medical Technology Co., Ltd. and the "full circulation" of domestic unlisted shares.
According to public information, 7LK Pomegranate Cloud Medicine was established in 2010 and has grown to become the largest online chronic disease prescription platform in China, potentially becoming the first Chinese chronic disease medical service stock listed on the Nasdaq in the U.S.
As the largest online chronic disease prescription platform in China, 7LK Pomegranate Cloud Medicine has accumulated over 400,000 registered doctors nationwide and more than 30 million users. It boasts a drug database covering detailed information on over 30,000 types of medications, with more than 10,000 commonly used drugs available on the Pomegranate Cloud Pharmacy. Its online consultation app, Pomegranate Cloud Medicine, has achieved an 80% market share for registered liver disease doctors nationwide, ranking first in the country, with a mature doctor retention rate of 99.5%, firmly placing it at the top of the industry. Additionally, as of 2024, 7LK Pomegranate Cloud Medicine has been consecutively ranked among the Global Unicorn 500 for five years.
Since its launch, 7LK Pomegranate Cloud Medicine has attracted significant attention and favor from renowned domestic and international investment institutions, securing multiple rounds of financing. Investors include Changjiang Guohong Investment, Jiangsu High-Tech Investment Group, Sequoia Capital, JD Group, Bangsheng Capital, Zhongke Kechuang, Buchang Pharmaceuticals, Meinian Onehealth Healthcare, Jinglin Investment, Gaoteg Investment Group, China General Investment, Relay Fund, and Focus Media, among dozens of industrial capital and well-known venture capital institutions. This robust capital support has laid a solid foundation for its continuous innovation and expansion, helping it pioneer new advancements in the field of internet-based chronic disease management.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
